AAM Archives

African Association of Madison, Inc.

AAM@LISTSERV.ICORS.ORG

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Felix Ossia <[log in to unmask]>
Reply To:
AAM (African Association of Madison)
Date:
Fri, 13 Dec 2002 19:03:16 -0600
Content-Type:
text/plain
Parts/Attachments:
text/plain (68 lines)
Friday, 13 December, 2002, 10:53 GMT - BBC, London
Success in malaria drug tests

Scientists have announced promising results from tests of a new
treatment for malaria patients.
It could prove a valuable additional weapon at a time the malaria
parasite is gaining resistance to conventional drug treatments in many
parts of the world.

However, further trials will be needed before it can be declared safe
and effective - it has not yet been tested in children, who account for
most malaria deaths in developing countries.

Writing in the medical journal The Lancet, the scientists, from the
University of Tubingen in Germany, say that - when they administered a
particular antibiotic to malaria patients in the West African state of
Gabon - up to 90% of patients recovered in two weeks.

The preliminary trials involved an antibiotic called fosmidomycin.

Laboratory tests suggest it works by stopping the parasite that causes
malaria from producing a chemical it needs to survive.

Small groups of adult Africans already suffering from malaria were given
the treatment over several days.

The results have been promising - within two weeks, cure rates in
different groups were reported to have been at least 60% and in some
cases as high as 89%.

It is early days, but the scientists say they this is a good start.

Note of caution

Writing in the Lancet, Dr Kremsner, from the University of Tubingen,
said: "These data suggest that fosmidomycin is a safe and effective
treatment for malaria in adult Africans if given for four days or more."


However, he warned that the results should be interpreted cautiously as
not only were the study groups small, but there was possibly an
increased risk of the patient being the source of further infections
after taking the drug.

However, the team wants to test the antibiotic on children.

Malaria has been and remains a deadly foe in sub-Saharan Africa, where a
child is estimated to die from its effects every 30 seconds.

Much work has been taking place over the last decade to battle it on
several fronts:

to improve preventative measures - such as nets - to stop people getting
malaria in the first place;
to develop better drugs to tackle malaria once they have caught it;
to eradicate malaria-carrying mosquitoes;
to improve mosquito repellents.
An effective malaria vaccine may be available in 10 years or so,
scientists hope.

----------------------------------------------------------------------------
To unsubscribe/subscribe or view archives of postings, visit:

        http://maelstrom.stjohns.edu/archives/aam.html

AAM Website:  http://www.danenet.wicip.org/aam
----------------------------------------------------------------------------

ATOM RSS1 RSS2